Ligand Conjugated Low-Density Lipoprotein Nanoparticles for Enhanced Optical Cancer Imaging in Vivo
Journal of the American Chemical Society2007Vol. 129(18), pp. 5798–5799
Citations Over TimeTop 10% of 2007 papers
Abstract
LDL particles are high-capacity nanocarriers with precisely controlled size and are naturally biocompatible, biodegradable, and nonimmunogenic. However, their utilities as drug carriers are limited by the narrow purview of LDL receptor-positive tumors. Here, we synthsized a ligand-conjugated, NIR-labeled LDL that enables the first in vivo demonstration of rerouting LDL from LDL receptors to selected alternate receptors, thus drastically expanding the range of using LDL particles as nanocarriers for in vivo cancer imaging and treatment.
Related Papers
- → Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity(1998)222 cited
- → Glycoprotein 330/Low Density Lipoprotein Receptor-related Protein-2 Mediates Endocytosis of Low Density Lipoproteins via Interaction with Apolipoprotein B100(1995)101 cited
- → Biocompatible Nanocarriers for Enhanced Cancer Photodynamic Therapy Applications(2021)34 cited
- → Mixed Biocompatible Block Copolymer/Lipid Nanostructures as Drug Nanocarriers: Advantages and Pharmaceutical Perspectives(2015)
- → Biosynthesis and Processing of Low Density Lipoprotein (LDL) Receptor in the Fibroblasts of Internalization-Defective Type Familial Hypercholesterolemia(1987)